A lcoholic hepatitis, a severe manifestation of alcoholic liver disease, is rising in incidence. Complete abstinence from alcohol remains the cornerstone of treatment, while other specifi c interventions aim to decrease short-term mortality rates.
Despite current treatments, about 25% of patients with severe alcoholic hepatitis eventually die of it. For those who survive hospitalization, measures need to be taken to prevent recidivism. Although liver transplantation seems to hold promise, early transplantation is still largely experimental in alcoholic hepatitis and will likely be available to only a small subset of patients, especially in view of ethical issues and the possible wider implications for transplant centers.
New treatments will largely depend on a better understanding of the disease's pathophysiology, and future clinical trials should evaluate therapies that improve short-term as well as long-term outcomes.
■ ACUTE HEPATIC DECOMPENSATION IN A HEAVY DRINKER
Excessive alcohol consumption is very common worldwide, is a major risk factor for liver disease, and is a leading cause of preventable death. Alcoholic cirrhosis is the eighth most common cause of death in the United States and in 2010 was responsible for nearly half of cirrhosis-related deaths worldwide. 
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10% to 20% progress to cirrhosis, and of those with cirrhosis, 1% to 2% are diagnosed with hepatocellular carcinoma every year. 2 Within this spectrum, alcoholic hepatitis is a well-defi ned clinical syndrome characterized by acute hepatic decompensation that typically results from long-standing alcohol abuse. Binge drinkers may also be at risk for alcoholic hepatitis, but good data on the association between drinking patterns and the risk of alcoholic hepatitis are limited.
Alcoholic hepatitis varies in severity from mild to life-threatening. 3 Although its exact incidence is unknown, its prevalence in alcoholics has been estimated at 20%. 4 Nearly half of patients with alcoholic hepatitis have cirrhosis at the time of their acute presentation, and these patients generally have a poor prognosis, with a 28-day death rate as high as 50% in severe cases. 5, 6 Moreover, although alcoholic hepatitis develops in only a subset of patients with alcoholic liver disease, hospitalizations for it are increasing in the United States. 7 Women are at higher risk of developing alcoholic hepatitis, an observation attributed to the effect of estrogens on oxidative stress and infl ammation, lower gastric alcohol dehydrogenase levels resulting in slower fi rst-pass metabolism of alcohol, and higher body fat content causing a lower volume of distribution for alcohol than in men. 8 The incidence of alcoholic hepatitis is also infl uenced by a number of demographic and genetic factors as well as nutritional status and coexistence of other liver diseases. 9 Most patients diagnosed with alcoholic hepatitis are active drinkers, but it can develop even after signifi cantly reducing or stopping alcohol consumption.
■ FATTY ACIDS, ENZYMES, CYTOKINES, INFLAMMATION
Alcohol consumption induces fatty acid synthesis and inhibits fatty acid oxidation, thereby promoting fat deposition in the liver. The major enzymes involved in alcohol metabolism are cytochrome P450 2E1 (CYP2E1) and alcohol dehydrogenase. CYP2E1 is inducible and is up-regulated when excess alcohol is ingested, while alcohol dehydrogenase function is relatively stable. Oxidative degradation of alcohol by these enzymes generates reactive oxygen species and acetaldehyde, inducing liver injury. 10 Interestingly, it has been proposed that variations in the genes for these enzymes infl uence alcohol consumption and dependency as well as alcohol-driven tissue damage.
In addition, alcohol disrupts the intestinal mucosal barrier, allowing lipopolysaccharides from gram-negative bacteria to travel to the liver via the portal vein. These lipopolysaccharides then bind to and activate sinusoidal Kupffer cells, leading to production of several cytokines such as tumor necrosis factor alpha, interleukin 1, and transforming growth factor beta. These cytokines promote hepatocyte infl ammation, apoptosis, and necrosis (FIGURE 1).
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Besides activating the innate immune system, the reactive oxygen species resulting from alcohol metabolism interact with cellular components, leading to production of protein adducts. These act as antigens that activate the adaptive immune response, followed by Band T-lymphocyte infi ltration, which in turn contribute to liver injury and infl ammation. 12 
■ THE DIAGNOSIS IS MAINLY CLINICAL
The diagnosis of alcoholic hepatitis is mainly clinical. In its usual presentation, jaundice develops rapidly in a person with a known history of heavy alcohol use. Other symptoms and signs may include ascites, encephalopathy, and fever. On examination, the liver may be enlarged and tender, and a hepatic bruit has been reported. 13 Other classic signs of liver disease such as parotid enlargement, Dupuytren contracture, dilated abdominal wall veins, and spider nevi Women are at higher risk of developing alcoholic hepatitis In the acute setting, typical biochemical derangements in alcoholic hepatitis include elevated AST (up to 2 to 6 times the upper limit of normal; usually less than 300 IU/L) and elevated ALT to a lesser extent, 14 with an AST-to-ALT ratio greater than 2. Neutrophilia, anemia, hyperbilirubinemia, and coagulopathy with an elevated international normalized ratio are common.
Patients with alcoholic hepatitis are also prone to develop bacterial infections, and about 7% develop hepatorenal syndrome, itself an ominous sign. 15 Imaging studies are valuable in excluding other causes of abnormal liver test results in patients who abuse alcohol, such as biliary obstruction, infi ltrative liver diseases, and hepatocellular carcinoma. Screen for alcohol intake During the initial evaluation of suspected alcoholic hepatitis, one should screen for excessive drinking. In a US Centers for Disease Control and Prevention study, only one of six US adults, including binge drinkers, said they had ever discussed alcohol consumption with a health professional. 16 Many patients with alcoholic liver disease in general and alcoholic hepatitis in particular deny alcohol abuse or underreport their intake. 17 Screening tests such as the CAGE questionnaire and the Alcohol Use Disorders Identifi cation Test can be used to assess alcohol dependence or abuse. 18, 19 The CAGE questionnaire consists of four questions:
• Have you ever felt you should cut down on your drinking? • Have people annoyed you by criticizing your drinking?
• Have you ever felt guilty about your drinking? • Have you ever had a drink fi rst thing in the morning (an eye-opener) to steady your nerves or to get rid of a hangover? A yes answer to two or more questions is considered clinically signifi cant.
Is liver biopsy always needed?
Although alcoholic hepatitis can be suspected on the basis of clinical and biochemical clues, liver biopsy remains the gold standard diagnostic tool. It confi rms the clinical diagnosis of alcoholic hepatitis in about 85% of all patients and in up to 95% when signifi cant hyperbilirubinemia is present. 20 However, whether a particular patient needs a biopsy is not always clear. The American Association for the Study of Liver Diseases (AASLD) recommends biopsy in patients who have a clinical diagnosis of severe alcoholic hepatitis for whom medical treatment is being considered and in those with an uncertain underlying diagnosis.
Findings on liver biopsy in alcoholic hepatitis include steatosis, hepatocyte ballooning, neutrophilic infi ltration, Mallory bodies (which represent aggregated cytokeratin intermediate fi laments and other proteins), and scarring with a typical perivenular distribution as opposed to the periportal fi brosis seen in chronic viral hepatitis. Some histologic fi ndings, such as centrilobular necrosis, may overlap alcoholic hepatitis and nonalcoholic steatohepatitis.
In addition to confi rming the diagnosis and staging the disease, liver biopsy has prognostic value. The severity of infl ammation and cholestatic changes correlates with poor prognosis and may also predict response to corticosteroid treatment in severe cases of alcoholic hepatitis. 21 However, the utility of liver biopsy in confi rming the diagnosis and assessing the prognosis of alcoholic hepatitis is controversial for several reasons. Coagulopathy, thrombocytopenia, and ascites are all common in patients with alcoholic hepatitis, often making percutaneous liver biopsy contraindicated. Transjugular liver biopsy is not universally available outside tertiary care centers.
Needed is a minimally invasive test for 
FIGURE 1
Alcohol increases intestinal permeability, which allows the translocation of bacterial lipopolysaccharides to the liver through the portal circulation. Antilipopolysaccharide immunoglobulin can potentially attenuate this process.
Alcohol incudes hepatocyte injury through several mechanisms. The fi nal common pathway leads to liver tissue infl ammation, fi brosis, and necrosis.
Lipopolysaccharides bind to Toll-like receptors and activate Kupffer cells, which in turn release a number of cytokines such as tumor necrosis factor (TNF) alpha, interleukin 1 (IL-1), and interleukin 6 (IL-6) that promote tissue infl ammation. TNF alpha also mediates cellular apoptosis and necrosis by activating death-induction molecules known as caspases. Anakinra (an IL-1 antagonist) and emricasan (a caspase protease inhibitor) could minimize alcohol-induced liver injury. Alcohol assessing this disease. Breath analysis might be such a test, offering a noninvasive means to study the composition of volatile organic compounds and elemental gases and an attractive method to evaluate health and disease in a patient-friendly manner. Our group devised a model based on breath levels of trimethylamine and pentane. When we tested it, we found that it distinguishes patients with alcoholic hepatitis from those with acute liver decompensation from causes other than alcohol and controls without liver disease with up to 90% sensitivity and 80% specifi city. 22 
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■ ASSESSING THE SEVERITY OF ALCOHOLIC HEPATITIS
Several models have been developed to assess the severity of alcoholic hepatitis and guide treatment decisions (TABLE 2) . The MDF (Maddrey Discriminant Function) 6 system was the fi rst scoring system developed and is still the most widely used. A score of 32 or higher indicates severe alcoholic hepatitis and has been used as the threshold for starting treatment with corticosteroids. 6 The MDF has limitations. Patients with a score lower than 32 are considered not to have severe alcoholic hepatitis, but up to 17% of them still die. Also, since it uses the prothrombin time, its results can vary considerably among laboratories, depending on the sensitivity of the thromboplastin reagent used.
The MELD (Model for End-stage Liver Disease) score. Sheth et al 23 compared the MELD and the MDF scores in assessing the severity of alcoholic hepatitis. They found that the MELD performed as well as the MDF in predicting 30-day mortality. A MELD score of greater than 11 had a sensitivity in predicting 30-day mortality of 86% and a specifi city of 81%, compared with 86% and 48%, respectively, for MDF scores greater than 32.
Another study found a MELD score of 21 to have the highest sensitivity and specificity in predicting mortality (an estimated 90-day death rate of 20%). Thus, a MELD score of 21 is an appropriate threshold for prompt consideration of specifi c therapies such as corticosteroids. 24 The MELD score has become increasingly important in patients with alcoholic hepatitis, as some of them may become candidates for liver transplantation (see below). Also, serial MELD scores in hospitalized patients have prognostic implications, since an increase of 2 or more points in the fi rst week has been shown to predict in-hospital mortality.
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The GAHS (Glasgow Alcoholic Hepatitis Score) 26 was shown to identify patients with alcoholic hepatitis who have an especially poor prognosis and need corticosteroid therapy. In those with a GAHS of 9 or higher, the 28-day survival rate was 78% with corticosteroid treatment and 52% without corticosteroid treatment; survival rates at 84 days were 59% and 38%, respectively. The Lille score. 28 While the above scores are used to identify patients at risk of death from alcoholic hepatitis and to decide on starting corticosteroids, the Lille score is designed to assess response to corticosteroids after 1 week of treatment. It is calculated based on five pretreatment variables and the change in serum bilirubin level at day 7 of corticosteroid therapy. Lille scores range from 0 to 1; a score higher than 0.45 is associated with a 75% mortality rate at 6 months and indicates a lack of response to corticosteroids and that these drugs should be discontinued. 28 
■ MANAGEMENT
Supportive treatment
Abstinence from alcohol is the cornerstone of treatment of alcoholic hepatitis. Early management of alcohol abuse or dependence is, therefore, warranted in all patients with alcoholic hepatitis. Referral to addiction specialists, motivational therapies, and anticraving drugs such as baclofen can be utilized.
Treat alcohol withdrawal. Alcoholics who suddenly decrease or discontinue their alcohol use are at high risk of alcohol withdrawal synUsual presentation: rapid onset of jaundice in a person with a history of heavy alcohol use DUGUM AND COLLEAGUES drome. Within 24 hours after the last drink, patients can experience increases in their heart rate and blood pressure, along with irritability and hyperrefl exia. Within the next few days, more dangerous complications including seizures and delirium tremens can arise.
Alcohol withdrawal symptoms should be treated with short-acting benzodiazepines or clomethiazole, keeping the risk of worsening encephalopathy in mind. 29 If present, complications of cirrhosis such as encephalopathy, ascites, and variceal bleeding should be managed.
Nutritional support is important. Proteincalorie malnutrition is common in alcoholics, as are defi ciencies of vitamin A, vitamin D, thiamine, folate, pyridoxine, and zinc. 30 Although a randomized controlled trial comparing enteral nutrition (2,000 kcal/day) vs corticosteroids (prednisolone 40 mg/day) in patients with alcoholic hepatitis did not show any difference in the 28-day mortality rate, those who received nutritional support and survived the fi rst month had a lower mortality rate than those treated with corticosteroids Typical biochemical derangements include elevated AST and, to a lesser extent, ALT (8% vs 37%). 31 A daily protein intake of 1.5 g per kilogram of body weight is therefore recommended, even in patients with hepatic encephalopathy. 15 Combining enteral nutrition and corticosteroid treatment may have a synergistic effect but is yet to be investigated.
Screen for infection. Patients with alcoholic hepatitis should be screened for infection, as about 25% of those with severe alcoholic hepatitis have an infection at admission. 32 Since many of these patients meet the criteria for systemic infl ammatory response syndrome, infections can be particularly diffi cult to diagnose. Patients require close clinical monitoring as well as regular pancultures for early detection. Antibiotics are frequently started empirically even though we lack specifi c evidence-based guidelines on this practice.
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Corticosteroids
Various studies have evaluated the role of corticosteroids in treating alcoholic hepatitis, differing considerably in sample populations, methods, and end points. Although the results of individual trials differ, meta-analyses indicate that corticosteroids have a moderate benefi cial effect in patients with severe alcoholic hepatitis.
For example, Rambaldi et al 34 performed a meta-analysis that concluded the mortality rate was lower in alcoholic hepatitis patients with MDF scores of at least 32 or hepatic encephalopathy who were treated with corticosteroids than in controls (relative risk 0.37, 95% confi dence interval 0.16-0.86).
Therefore, in the absence of contraindications, the AASLD recommends starting corticosteroids in patients with severe alcoholic hepatitis, defi ned as an MDF score of 32 or higher. 21 The preferred agent is oral prednisolone 40 mg daily or parenteral methylprednisolone 32 mg daily for 4 weeks and then tapered over the next 2 to 4 weeks or abruptly discontinued. Because activation of prednisone is decreased in patients with liver disease, prednisolone (the active form) is preferred over prednisone (the inactive precursor). 35 In alcoholic hepatitis, the number needed to treat with corticosteroids to prevent one death has been calculated 36 at 5. As mentioned, response to corticosteroids is commonly assessed at 1 week of treatment using the Lille score. A score higher than 0.45 predicts a poor response and should trigger discontinuation of corticosteroids, particularly in those classifi ed as null responders (Lille score > 0.56).
Adverse effects of steroids include sepsis, gastrointestinal bleeding, and steroid psychosis. Of note, patients who have evidence of hepatorenal syndrome or gastrointestinal bleeding tend to have a less favorable response to corticosteroids. Also, while infections were once considered a contraindication to steroid therapy, recent evidence suggests that steroid use might not be precluded in infected patients after appropriate antibiotic therapy.
Infections occur in about a quarter of all alcoholic hepatitis patients treated with steroids, more frequently in null responders (42.5%) than in responders (11.1%), which supports corticosteroid discontinuance at 1 week in null responders.
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Pentoxifylline An oral phosphodiesterase inhibitor, pentoxifylline, also inhibits production of several cytokines, including tumor necrosis factor alpha. At a dose of 400 mg orally three times daily for 4 weeks, pentoxifylline has been used in treating severe alcoholic hepatitis (MDF score ≥ 32) and is recommended especially if corticosteroids are contraindicated, as with sepsis. 21 An early double-blind clinical trial randomized patients with severe alcoholic hepatitis to receive either pentoxifylline 400 mg orally three times daily or placebo. Of the patients who received pentoxifylline, 24.5% died during the index hospitalization, compared with 46.1% of patients who received placebo. This survival benefi t was mainly related to a markedly lower incidence of hepatorenal syndrome as the cause of death in the pentoxifylline group than in the placebo group (50% vs 91.7% of deaths). 37 In a small clinical trial in patients with severe alcoholic hepatitis, pentoxifylline recipients had a higher 3-month survival rate than prednisolone recipients (35.29% vs 14.71%, P = .04). 38 However, a larger trial showed no improvement in 6-month survival with the combination of prednisolone and pentoxifylline compared with prednisolone alone (69.9% vs DUGUM AND COLLEAGUES 69.2%, P = .91). 39 Also, a meta-analysis of fi ve randomized clinical trials found no survival benefi t with pentoxifylline therapy. 40 Of note, in the unfortunate subgroup of patients who have a poor response to corticosteroids, no alternative treatment, including pentoxifylline, has been shown to be effective.
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Prednisone or pentoxifylline? Very recently, results of the Steroids or Pentoxifylline for Alcoholic Hepatitis (STOPAH) trial have been released. 42 This is a large, multicenter, double-blinded clinical trial that aimed to provide a defi nitive answer to whether corticosteroids or pentoxifylline (or both) are benefi cial in patients with alcoholic hepatitis.
The study included 1,103 adult patients with severe alcoholic hepatitis (MDF score ≥ 32) who were randomized to monotherapy with prednisolone or pentoxifylline, combination therapy, or placebo. The primary end point was mortality at 28 days, and secondary end points included mortality at 90 days and at 1 year. Prednisolone reduced 28-day mortality by about 39%. In contrast, the 28-day mortality rate was similar in patients who received pentoxifylline and those who did not. Also, neither drug was signifi cantly associated with a survival benefi t beyond 28 days. The investigators concluded that pentoxifylline has no impact on disease progression and should not Other tumor necrosis factor alpha inhibitors not recommended Two other tumor necrosis factor alpha inhibitors, infl iximab and etanercept, have been tested in clinical trials in alcoholic hepatitis. Unfortunately, the results were not encouraging, with no major reduction in mortality. [43] [44] [45] In fact, these trials demonstrated a signifi cantly increased risk of infections in the treatment groups. Therefore, these drugs are not recommended for treating alcoholic hepatitis. A possible explanation is that tumor necrosis factor alpha plays an important role in liver regeneration, aiding in recovery from alcohol-induced liver injury, and inhibiting it can have deleterious consequences.
Other agents
A number of other agents have undergone clinical trials in alcoholic hepatitis.
N-acetylcysteine, an antioxidant that replenishes glutathione stores in hepatocytes, was evaluated in a randomized clinical trial in combination with prednisolone. 46 Although the 1-month mortality rate was signifi cantly lower in the combination group than in the prednisolone-only group (8% vs 24%, P = .006), 3-month and 6-month mortality rates were not. Nonetheless, the rates of infection and hepatorenal syndrome were lower in the combination group. Therefore, corticosteroids and N-acetylcysteine may have synergistic effects, but the optimum duration of N-acetylcysteine therapy needs to be determined in further studies.
Vitamin E, silymarin, propylthiouracil, colchicine, and oxandrolone (an anabolic steroid) have also been studied, but with no convincing benefi t.
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Role of liver transplantation Liver transplantation for alcoholic liver disease has been a topic of great medical and social controversy. The view that alcoholic patients are responsible for their own illness led to caution when contemplating liver transplantation. Many countries require 6 months of abstinence from alcohol before placing a patient on the liver transplant list, posing a major obstacle to patients with alcoholic hepatitis, as almost all are active drinkers at the time of presentation and many will die within 6 months. Reasons for this 6-month rule include donor shortage and risk of recidivism. 47 With regard to survival following alcoholic hepatitis, a study utilizing the United Network for Organ Sharing database matched patients with alcoholic hepatitis and alcoholic cirrhosis who underwent liver transplantation. Rates of 5-year graft survival were 75% in those with alcoholic hepatitis and 73% in those with alcoholic cirrhosis (P = .97), and rates of patient survival were 80% and 78% (P = .90), respectively. Proportional regression analysis adjusting for other variables showed no impact of the etiology of liver disease on graft or patient survival. The investigators concluded that liver transplantation could be considered in a select group of patients with alcoholic hepatitis who do not improve with medical therapy. 48 In a pivotal case-control prospective study, 49 26 patients with Lille scores greater than 0.45 were listed for liver transplantation within a median of 13 days after nonresponse to medical therapy. The cumulative 6-month survival rate was higher in patients who received a liver transplant early than in those who did not (77% vs 23%, P < .001). This benefi t was maintained through 2 years of follow-up (hazard ratio 6.08, P = .004). Of note, all these patients had supportive family members, no severe coexisting conditions, and a commitment to alcohol abstinence (although 3 patients resumed drinking after liver transplantation). 49 Although these studies support early liver transplantation in carefully selected patients with severe alcoholic hepatitis, the criteria for transplantation in this group need to be refi ned. Views on alcoholism also need to be reconciled, as strong evidence is emerging that implicates genetic and environmental infl uences on alcohol dependence. FIGURE 2 shows a suggested management algorithm for alcoholic hepatitis, adapted from the guidelines of the AASLD and European Association for the Study of the Liver.
Management algorithm
Abstinence from alcohol is the cornerstone of treatment of alcoholic hepatitis ■ NEW THERAPIES NEEDED
Novel therapies for severe alcoholic hepatitis are urgently needed to help combat this devastating condition. Advances in understanding its pathophysiology have uncovered several new therapeutic targets, and new agents are already being evaluated in clinical trials.
IMM 124-E, a hyperimmune bovine colostrum enriched with immunoglobulin G antilipopolysaccharide, is going to be evaluated in combination with prednisolone in patients with severe alcoholic hepatitis.
Anakinra, an interleukin 1 receptor antagonist, has signifi cant anti-infl ammatory activity and is used to treat rheumatoid arthritis. A clinical trial to evaluate its role in alcoholic hepatitis has been designed in which patients with severe alcoholic hepatitis (defi ned as a MELD score ≥ 21) will be randomized to receive either methylprednisolone or a combination of anakinra, pentoxifylline, and zinc (a mineral that improves gut integrity).
Emricasan, an orally active caspase protease inhibitor, is another agent currently being tested in a phase 2 clinical trial in patients with severe alcoholic hepatitis. Since caspases induce apoptosis, inhibiting them should theoretically dampen alcohol-induced hepatocyte injury.
Interleukin 22, a hepatoprotective cytokine, shows promise as a treatment and will soon be evaluated in alcoholic hepatitis. ■
